SCHEMBL6029200

SCHEMBL6029200

COc1ccc(-c2cnc(OCC(=O)NC(Cc3ccc(Cl)c(Cl)c3)C3CCCNC3)nc2)cc1OC

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 1/20 0.38
ROCK1 Q13464 1/20 0.38
DYRK1A Q13627 1/20 0.38
CLK4 Q9HAZ1 1/20 0.38
ALOX15 P16050 1/20 0.37
RXFP1 Q9HBX9 1/20 0.36
CCNT1 O60563 1/20 0.36
CDK9 P50750 1/20 0.36
IKBKB O14920 1/20 0.36
STK17B O94768 1/20 0.36
CDK2 P24941 1/20 0.36
AKT1 P31749 1/20 0.36
PDPK1 O15530 1/20 0.36
RPS6KB1 P23443 1/20 0.36
AAK1 Q2M2I8 1/20 0.35
GAK O14976 1/20 0.35
UTS2R Q9UKP6 1/20 0.35
LMNA P02545 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7827088 0.95 DYRK1A (0.39) ROCK2ROCK1DYRK1ACLK4IKBKB
SCHEMBL6029004 0.92 MAPK1 (0.39) ROCK2ROCK1RXFP1CDK9IKBKB
SCHEMBL6029151 0.91 CHEK1 (0.39) ROCK2ROCK1DYRK1ACLK4IKBKB
SCHEMBL6030392 0.89 CHEK1 (0.41) DYRK1ACLK4CDK9CDK2AKT1
SCHEMBL6029616 0.89 CDK2 (0.37) ROCK2ROCK1DYRK1ACLK4ALOX15
SCHEMBL6028227 0.88 LMNA (0.41) ROCK2ROCK1ALOX15CCNT1CDK9
SCHEMBL6029146 0.87 FYN (0.42) ROCK2ROCK1
SCHEMBL6029742 0.87 CDK9 (0.38) ROCK2ROCK1ALOX15RXFP1CCNT1
SCHEMBL7829880 0.86 AKT1 (0.42) ROCK2ROCK1DYRK1ACLK4IKBKB
Hydrochloric Acid SCHEMBL7833338 0.85 AKT1 (0.42) ROCK2ROCK1DYRK1ACLK4IKBKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6984643-B2 2,5-substituted pyrimidine derivatives-CCR-3 receptor antagonists ROCHE PALO ALTO LLC (US) 2006-01-10 US disclosed
EP-1521582-A1 2,5-SUBSTITUTED PYRIMIDINE DERIVATIVES AS CCR-3 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2005-04-13 EP disclosed
US-20040014775-A1 2,5-substituted pyrimidine derivatives-CCR-3 receptor antagonists ROCHE PALO ALTO LLC 2004-01-22 US disclosed
WO-2004004731-A1 2, 5-SUBSTITUTED PYRIMIDINE DERIVATIVES AS CCR-3 RECEPTOR ANTAGONISTS IX F. HOFFMANN-LA ROCHE AG (CH) 2004-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040014775-A1 2,5-substituted pyrimidine derivatives-CCR-3 receptor antagonists CCR3, CCR1, CCRL2 ROCK2 4172/4885ROCK1 4675/4885DYRK1A 3013/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.